| 发明名称 |
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF |
| 摘要 |
The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody. |
| 申请公布号 |
US2016017050(A1) |
申请公布日期 |
2016.01.21 |
| 申请号 |
US201514857112 |
申请日期 |
2015.09.17 |
| 申请人 |
ROCHE GLYCART AG |
发明人 |
Herting Frank;Klein Christian |
| 分类号 |
C07K16/30;A61K45/06;A61K39/395;C07K16/22 |
主分类号 |
C07K16/30 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. Use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297 for the manufacture of a medicament for the treatment of cancer in combination with an anti-VEGF antibody. |
| 地址 |
Schlieren CH |
